mouse anti human complement factor bb antibody (Bio-Rad)
Bio-Rad is a verified supplier 
Bio-Rad manufactures this product 
91
Structured Review
Bio-Rad
mouse anti human complement factor bb antibody
Mouse Anti Human Complement Factor Bb Antibody, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 91/100, based on 10 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/complement+factor+b/Mouse+anti+Human+Complement+Factor+I/pmc08223746-74-9-15
Average 91 stars, based on 10 article reviews
Mouse Anti Human Complement Factor Bb Antibody, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 91/100, based on 10 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/complement+factor+b/Mouse+anti+Human+Complement+Factor+I/pmc08223746-74-9-15
Average 91 stars, based on 10 article reviews
mouse anti human complement factor bb antibody - by Bioz Stars,
2026-10
91/100 stars
Images
1) Product Images from "Alternative Complement Pathway Is Activated and Associated with Galactose-Deficient IgA 1 Antibody in IgA Nephropathy Patients"
Article Title: Alternative Complement Pathway Is Activated and Associated with Galactose-Deficient IgA 1 Antibody in IgA Nephropathy Patients
Journal: Frontiers in Immunology
doi: 10.3389/fimmu.2021.638309
Figure Legend Snippet: Glomerular complement factor Bb and C3c deposits were detected in IgAN patients. (A, B) Mesangial positivity can be seen in the complement factor Bb and C3c stains on the glomerulus of a patients with IgA nephropathy. (C, D) No intensity can be detected in the complement factor Bb and C3c stains on the glomerulus of a patient with focal segmental sclerosis. (Magnification: 400X).
Techniques Used:
Figure Legend Snippet: Decreased activation of alternative and terminal complement pathway and stabilized renal function after immunosuppression. (A) eGFR decreased slightly among patients who did not receive immunosuppression ( P = 0.028). (B) No change in eGFR among patients received immunosuppression. (C) UPCR tended to decrease slightly among patients who did not receive immunosuppression ( P = 0.051). (D) UPCR decreased significantly in patients who received immunosuppression ( P < 0.0001). (E) Plasma Gd-IgA 1 level tended to decrease 1 months after immunosuppression (N = 17, P = 0.0638) and 3~6 months after immunosuppression (N = 20, P = 0.0019). (F) Plasma C5a significantly decreased 1 (N = 17, P < 0.0001) and 3~6 months after immunosuppression (N = 20, P < 0.0001). (G) Plasma factor Ba level significantly decreased 1 (N = 17, P = 0.0008) and 3~6 months after immunosuppression (N = 20, P = 0.0004). UPCR, urinary protein to creatinine ratio; eGFR, estimated glomerular filtration rate.
Techniques Used: Activation Assay, Clinical Proteomics, Filtration
Related Articles
Staining:Article Title: Alternative Complement Pathway Is Activated and Associated with Galactose-Deficient IgA 1 Antibody in IgA Nephropathy Patients Article Snippet: .. For factor Bb staining, tissue sections were incubated with Article Title: Sequential Increase in Complement Factor I, iC3b, and Cells Expressing CD11b or CD14 in Cutaneous Vasculitis. Article Snippet: The complement iC3b was stained using 0.06μg/ml mouse monoclonal antihuman iC3b (neo) antibody (catalog number A209, IgG2bκ, Quidel® Corporation, San Diego, CA, USA). .. CFI was stained using 20μg/ml Article Title: Sequential Increase in Complement Factor I, iC3b, and Cells Expressing CD11b or CD14 in Cutaneous Vasculitis Article Snippet: The complement iC3b was stained using 0.06 μ g/ml mouse monoclonal antihuman iC3b (neo) antibody (catalog number A209, IgG2b κ , Quidel® Corporation, San Diego, CA, USA). .. CFI was stained using 20 μ g/ml Incubation:Article Title: Alternative Complement Pathway Is Activated and Associated with Galactose-Deficient IgA 1 Antibody in IgA Nephropathy Patients Article Snippet: .. For factor Bb staining, tissue sections were incubated with |